DERM
$7.50
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
Recent News
Journey Medical (DERM) Publishes Positive Emrosi Phase 1 Microbiome Data
Journey Medical Corp (NASDAQ:DERM) is one of the best performing micro cap stocks in 2025. On January 4, Lake Street analyst Thomas Flaten reaffirmed a Buy rating on Journey Medical Corp (NASDAQ:DERM) with a $13 price target. Earlier on December 10, Journey Medical Corp published results from a Phase 1 clinical trial, focusing on Emrosi’s […]
Public companies account for 34% of Journey Medical Corporation's (NASDAQ:DERM) ownership, while institutions account for 33%
Key Insights The considerable ownership by public companies in Journey Medical indicates that they collectively have a...
What Makes Journey Medical Corporation (DERM) a Good Investment?
Summers Value Partners, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Summers Value Fund LP returned a net return of 20.4% net in Q3 2025, surpassing the 12.4% return of the Russell 2000 Index ETF (IWM) and the 12.5% return for the Russell […]
Journey Medical Corp (DERM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Journey Medical Corp (DERM) reports a 21% revenue increase and significant growth in Emrosi prescriptions, despite challenges from generic competition.
Compared to Estimates, Journey Medical (DERM) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Journey Medical (DERM) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.